11:30 AM - 1:00 PM
The Racquet Club of Philadelphia
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) is a pharmaceutical company developing novel therapeutic products to treat gastrointestinal diseases with an initial focus on lactose intolerance. Ritter expects to be the first FDA approved drug for the treatment of lactose intolerance. Other highlights: • RP-G28, Ritter's lead product, has been studied in a Phase 2a trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide • Phase 2b/3 underway, potential pivotal trial: Enrollment completed - Data readout expected in Q1 2017 • Unmet need with no FDA-approved drugs - $1.2 billion U.S. market opportunity for an Rx treatment • Limited physician and user satisfaction with current therapies (i.e.: avoidance of dairy foods or use of short-term lactase supplements or alternative dairy foods, such as Soy Milk and Non-dairy foods) • Strong intellectual property portfolio and NCE status. Ritter Pharma has 9 issued patents providing coverage through 2030. An additional 24 patent applications are pending in the U.S. and other key international markets.